



## **Cancer Prevention and Control CIRB Meeting Agenda**

**February 22, 2024**

---

### **I. Initial Review**

**UMI23-15-01**, Phase 1a/b Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP) (Version Date 12/04/23)

---

### **II. Amendment**

**EA1151**, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Version Date 01/08/24)

---

### **III. Continuing Review**

**A222001**, A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy (Version Date 09/14/22)

---

### **IV. Continuing Review**

**EA8184**, A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers (Version Date 03/20/23)

---

**V. Continuing Review**

**NRG-CC010**, A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (Version Date 06/14/22)

---

**VI. Continuing Review**

**UMI21-05-01**, Obeticholic Acid for Prevention in Barrett's Esophagus (Version Date 09/09/22)

---